Description
PrymaLab · Research use only
Vilon Peptide 20mg
Lys-Glu (KE) dipeptide bioregulator, 20 mg of freeze-dried powder per vial
Vilon is the dipeptide Lys-Glu, written KE, and at two residues it is the shortest compound in the Khavinson bioregulator series: synthetic peptides developed in St Petersburg, each assigned by its developers to a tissue, in Vilon’s case the thymus. This listing is a 20 mg vial of freeze-dried Vilon with its own lot certificate. Published Vilon research covers chromatin in leukocytes from people aged 75 to 88, digestive enzymes and induced bladder tumours in rats, and the group’s theory that short peptides act on genes.
Specifications
| Property | Value |
|---|---|
| Compound | Vilon Lys-Glu (KE); Khavinson thymic peptide bioregulator |
| CAS number | 45234-02-4 |
| Molecular formula | C11H21N3O5 |
| Theoretical mass | 275.3 Da |
| Sequence / structure | H-KE-OH (2 residues; free N- and C-termini) |
| Label claim | 20 mg/vial |
| Form | Lyophilized (freeze-dried) powder or cake in a sealed glass vial with a rubber stopper and aluminium crimp cap |
| Storage, sealed | −20 °C, desiccated, dark |
| Purity specification | 99.0% or higher by RP-HPLC |
| Lot certificate | Results for the lot now shipping are in the certificate panel on this page |
| Safety data sheet | PL-SDS-181 |
What the vial contains
The vial holds Vilon as the free dipeptide H-Lys-Glu-OH, with no acetyl, amide or other group on either end. The certificate gives the formula C11H21N3O5 and a theoretical mass of 275.3 Da, and the LC-MS identity result for each lot is the figure to compare with it. That check matters more than usual here, because Lys-Glu is also the opening pair of several longer peptides in the same series. Vesugen is Lys-Glu-Asp, and Livagen, Testagen, Prostamax and Pancragen each add a fourth residue to that, so a mass that matches the dipeptide rules all of them out.
Because the molecule is so small, 20 mg is a large molar amount: about 73 µmol, a little less once the residual water reported on the certificate is allowed for. Vilon is also sold already dissolved, as a Vilon preloaded pen and a Vilon nasal spray.
What the research covers
Where Vilon comes from
Vilon belongs to the bioregulator programme that Vladimir Khavinson led at the St Petersburg Institute of Bioregulation and Gerontology. The group isolated small peptides from organs and tissues and then synthesised short analogues of them, from dipeptides to tetrapeptides, out of single amino acids1. Vilon is one of those analogues. Nearly all of the work on it comes from Khavinson’s group and its collaborators, and most of it appeared in the Bulletin of Experimental Biology and Medicine, which publishes Russian research in English translation.
The proposed mechanism
The group’s explanation for how such a small molecule could act centres on the genome. A 2021 systematic review by Khavinson and colleagues argued that peptides of two to seven residues can pass into the nucleus and nucleolus, bind nucleosomes, histone proteins and single- or double-stranded DNA, and influence DNA methylation, which switches genes on and off2. The most direct evidence for nuclear entry among these references is a 2011 study that tracked fluorescently labelled short peptides into the cytoplasm, nucleus and nucleolus of HeLa cells3. Vilon was not one of the labelled peptides; the experiment used Epitalon, Pinealon and Testagen3.
Studies that used Vilon
In cells from older people, Khavinson, Lezhava and Malinin compared five short peptides, Vilon among them, in leukocytes from subjects aged 75 to 884. All five activated ribosomal genes, loosened densely packed chromatin and released genes that had been silenced by age-related condensation4. Vilon did not share one further effect: only Epitalon, Livagen and Prostamax decondensed the structural heterochromatin beside the centromere of chromosome 14.
Two rat papers appeared in 2001. In the first, male and female Wistar rats aged 3 and 11 months were given Vilon by mouth, and the activity of invertase, maltase, alkaline phosphatase and amino- and dipeptidases changed along the digestive tract5. The rise was largest in the 11-month-old animals, which narrowed the gap between the age groups5. In the second, Pliss and colleagues induced bladder tumours with the carcinogen N-butyl-N-(4-hydroxybutyl)nitrosamine. Tumours developed in 56% of the rats given Vilon and in 75.5% of controls, and preneoplastic and early neoplastic changes in the bladder lining were half as frequent with Vilon6.
What is not established
The Vilon evidence is narrow. The papers come from one programme, their abstracts give few or no group sizes, and no study from an unrelated laboratory appears among them. None reports a receptor or specific binding partner for Vilon, and the nuclear-entry and DNA-binding experiments that the mechanism rests on used other peptides3. The leukocyte study measured chromatin structure rather than any function of the cells4. None of this work used PrymaLab material. The Vilon guide and the peptide bioregulators research overview cover the wider literature.
How each lot is tested
Every lot is tested in PrymaLab’s own laboratory in Ashland, Kentucky before release: RP-HPLC for purity, LC-MS for identity, Karl Fischer titration for water, LAL for endotoxin and USP <71> for sterility. The results for the lot now shipping are in the certificate panel on this page, and the certificate number, key and QR code can be checked on the verify page. These are in-house results from PrymaLab Analytical, not an independent test, and the lab is not accredited to ISO 17025. The third-party testing guarantee on this page still applies: if any independent laboratory finds the wrong compound, or less than the stated purity or amount, the order is refunded and the cost of the test is reimbursed.
Frequently asked questions
What exactly is in the Vilon 20 mg vial?
20 mg of Vilon, the dipeptide H-Lys-Glu-OH with free ends, as white freeze-dried powder in a sealed glass vial. The theoretical mass is 275.3 Da. The lot certificate reports purity by RP-HPLC, identity by LC-MS, water content, endotoxin and sterility for the lot now shipping.
How should the vial be stored?
Sealed, at −20 °C, dry and away from light. Let the vial reach room temperature before opening so moisture does not condense on the powder. After reconstitution, keep the solution at 2 to 8 °C, protected from light, and use it within a period your laboratory has set.
How do I match a certificate to my vial?
Read the lot number printed on the vial label and find the certificate with the same number. The panel on this page shows the lot now shipping, earlier lots are on the testing results page, and the verify page confirms a certificate from its number and key.
How is the vial different from the Vilon pen and nasal spray?
The vial holds 20 mg of dry peptide kept frozen until your lab dissolves it. The pen holds 6 mg already dissolved in 3 mL of bacteriostatic water, and the spray bottle holds 10 mg in bacteriostatic water. Both solutions are kept at 2 to 8 °C and never frozen. The peptide is the same in all three.
What does the published research on Vilon show?
Papers from the Khavinson group report chromatin changes in leukocytes from people aged 75 to 88, altered digestive enzyme activity in rats, and fewer induced bladder tumours in rats. All of it comes from one programme, the gene-regulation mechanism is a hypothesis, and none of it establishes any clinical use.
Can Vilon be used in people or animals?
No. This vial is sold for laboratory research only. Vilon is not approved by the FDA or any other authority for human or veterinary use and must not be given to people or animals.
References
- Anisimov VN, Khavinson VKh. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139-49. DOI · PubMed
- Khavinson VK, Popovich IG, Linkova NS, et al. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021;26(22). DOI · PubMed
- Fedoreyeva LI, Kireev II, Khavinson VKh, et al. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Mosc). 2011;76(11):1210-9. DOI · PubMed
- Khavinson VKh, Lezhava TA, Malinin VV. Effects of short peptides on lymphocyte chromatin in senile subjects. Bull Exp Biol Med. 2004;137(1):78-81. DOI · PubMed
- Khavinson VK, Timofeeva NM, Malinin VV, et al. Effect of the dipeptide vilon on activity of digestive enzyme in rats of various ages. Bull Exp Biol Med. 2001;131(6):583-5. DOI · PubMed
- Pliss GB, Mel'nikov AS, Malinin VV, et al. Inhibitory effect of peptide vilon on the development of induced rat urinary bladder tumors in rats. Bull Exp Biol Med. 2001;131(6):558-60. DOI · PubMed
Research use only
For laboratory research use only. Vilon Peptide 20mg is not a drug, food, cosmetic or dietary supplement, is not approved by the FDA or any comparable authority for human or veterinary use, and must not be given to people or animals. It is sold to qualified researchers and institutions, and the buyer is responsible for lawful handling and disposal.
Reviews
There are no reviews yet.